Navigation Links
Trans fatty acids increase the risk of gallstone disease

Several studies have shown that consumption of trans fatty acids leads to development of diabetes//, cancer and cardiovascular disease. Trans fatty acids are the hydrogenated and partially hydrogenated oil present in some margarines, candies, baked goods and many processed foods. They are produced commercially in large quantities by heating vegetable oils in the presence of metal catalysts and in the process the poly unsaturated fatty acids are removed. Trans fatty acids increase LDL cholesterol (the bad cholesterol) and decrease HDL cholesterol (the good cholesterol)thereby increasing the risk of heart disease.

A prospective study published in the May issue of the Archives of Internal Medicine has shown that higher consumption of trans fatty acids increased the risk of gallstone disease. The study was performed by applying a semi quantitative questionnaire that had questions relating to the food and frequency of food intake to a cohort of nearly 46000 men twice a year. Patients diagnosed with gallstone disease based on the X ray and cholecystectomy findings were recorded. During 14 years of follow-up, 2356 new cases of patients with symptoms who had gallstones were recorded. The result which was adjusted for difference in age and other associated risk factors showed that those men who had taken higher amounts trans fatty acids had a greater relative risk(1.23) of gallstone diseases compared with those who had taken lower amounts. Among the subtypes of trans fatty acids risk was more with trans-oleic fatty acid as compared to the other types.

Intake of the unsaturated vegetable oils from canola, peanuts, olive, flax, corn, safflower and sunflower which contain monounsaturated or polyunsaturated fatty acids that can reduce total cholesterol and increase HDL cholesterol levels assumes significant importance in this context. So play it safe by eating safe.

Reference : Arch Intern Med. 2005;165:997-1003.
'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with CAD
2. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
3. Stem Cell Transplants May Be Effective For MS Patients
4. Transforming stem cells to lung cells
5. Alternative to blood Transfusions
6. Need for Blood Transfusions reduced
7. Drugs Deter Heart Disease for Transplant Patients
8. Better Drug for Heart Transplant
9. Kidney Failure after Non-Kidney Transplants
10. Measles Risk in Transplant Patients
11. West Nile and Blood Transfusions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... , ... Rob Lowe is a popular actor that has been in many ... educational purpose as the host of the “Informed” series. The program focuses on many ... the series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... Economics Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis ... (IRR) field. Offering practical takeaways to apply immediately to IRR programs, the report ...
(Date:4/27/2017)... ... April 27, 2017 , ... Last night, Christine Collins of ... Year for her extraordinary compassion and lifelong dedication to serve others. Since 1997, ... for the prestigious award each year – identifying a CAREGiver who has exemplified ...
(Date:4/27/2017)... , ... April 27, 2017 , ... Are you investing ... spike in water-related accidents and drownings during the summer. While most of us assume ... these situations occur every day. Very few people are taking the time to learn ...
(Date:4/26/2017)... ... ... Journal of Oral Implantology – Tooth loss is not simply an ... complications with speech, eating, and overcompensation of mouth due to the deficiency. To combat ... number of tooth replacements increase, it is imperative to design an implant that will ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
Breaking Medicine Technology: